golcadomide
Sponsor Bristol Myers Squibb CO · listed as BMY
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2027-08-09
As disclosedAug 9, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06356129
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorCelgene
Listed asBMY
Condition(s)Large B-cell Lymphoma
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More BMY catalysts